CLINICAL TRIALS OF CANCER IMMUNOTHERAPIES

Transcription

1 CLINICAL TRIALS OF CANCER IMMUNOTHERAPIES B001 Preliminary clinical activity and safety of an autologous AdHER2 dendritic cell vaccine in patients with advanced metastatic HER2+ solid tumors. Lauren V. Wood 1, Brenda D. Roberson 1, Piyush Agarwal 1, Andrea A. Apolo 1, David Stroncek 2, Lou M. Weiner 3, John C. Morris 4, Jason C. Steel 5, Masaki Terabe 1, MIn-Jung Lee 1, Jane Trepel 1, Sohee Shim 1, Jay A. Berzofsky 1. 1 National Cancer Institute, Bethesda, MD; 2 NIH Clinical Center, Bethesda, MD; 3 Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; 4 University of Cincinnati, Cincinnati, OH; 5 The University of Queensland, Queensland, Australia. B002 TLR7/8-matured dendritic cells for therapeutic vaccination in AML: Results of a clinical Phase I/II trial. Katrin Deiser 1, Felix S. Lichtenegger 1, Frauke M. Schnorfeil 1, Thomas Köhnke 1, Torben Altmann 1, Veit Bücklein 1, Christian Augsberger 1, Andreas Moosmann 2, Monika Brüggemann 3, Mirjam HM Heemskerk 4, Beate Wagner 5, Wolfgang Hiddemann 1, Iris Bigalke 6, Gunnar Kvalheim 6, Marion Subklewe 1. 1 Klinikum der Universität München, LMU Munich, Munich, Germany; 2 Clinical Cooperation Group Immunotherapy at the Helmholtz Zentrum München, Munich, Germany; 3 Department of Hematology, University Hospital Schleswig-Holstein, Kiel, Germany; 4 Department of Hematology, Leiden University Medical Center, Leiden, Netherlands; 5 Department of Transfusion Medicine, Cellular Therapeutics and Hemostaseology, Klinikum der Universität München, LMU Munich, Munich, Germany; 6 Department of Cellular Therapy, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway. B003 A randomized controlled phase II clinical trial on mrna electroporated autologous dendritic cells for stage III/IV melanoma patients who are disease-free following the local treatment of macrometastases. Bart Neyns 1, Yanina Jansen 1, Jurgen Corthals 2, Sofie Wilgenhof 1, Max Schreuer 1, Carlo Heirman 2, Kris Thielemans 2. 1 University Hospital Vrije Universiteit Brussel, Brussel, Belgium; 2 Vrije Universiteit Brussel, Brussel, Belgium. B004 Peripheral blood immune profiling of anti-pd-1 therapy in human melanoma reveals a link between T cell re-invigoration and tumor burden that predicts response. Alexander Huang 1, Michael A. Postow 2, Robert J. Orlowski 1, Rosemarie Mick 1, Bertram Bengsch 1, Sasi Manne 1, Wei Xu 1, Shannon Harmon 1, Matthew Adamow 2, Deborah Kuk 2, Katherine Panangeas 2, Cristina Carerra 2, Phillip Wong 2, Felix Quagliarello 1, Kristen E. Pauken 1, Ramin S. Herati 1, Suzanne McGettigan 1, Shawn Kothari 1, Sangeeth M. George 1, Brandon Wenz 1, Kurt D'Andrea 1, Xiaowei Xu 1, Ravi K. Amaravadi 1, Giorgos Karakousis 1, Lynn M. Schuchter 1, Katherine L. Nathanson 1, Jedd D. Wolchok 2, Tara C. Gangadhar 1, John Wherry 1. 1 University of Pennsylvania, Philadelphia, PA; 2 Memorial Sloan Kettering Cancer Center, New York City, NY. This abstract is being presented as a short talk in Session 3 of the scientific program. B005 Cytokine production by intratumorally administered activated dendritic cells correlates with survival in a Phase I clinical trial in diverse cancers. Vivek Subbiah 1, Ravi Murthi 1, Robert Prins 2, Kyle Hendricks 3, Chitra Hosing 1, Lori Noffsinger 3, Mary McGuire 4, Robert Brown 4, Aung Naing 1, David Hong 1, Siqing Fu 1, Anthony Conley 1, Indreshpal Kaur 1, Sarah Campion 3, Marnix Bosch 5. 1 MD Anderson Cancer Center, Houston, TX; 2 UCLA, Los Angeles, CA; 3 Cognate Bioservices, Memphis, TN; 4 UT Health, Houston, TX; 5 NW Biotherapeutics, Bethesda, MD. B006 Large scale microarray profiling reveals four stages of immune escape in Non Hodgkin lymphomas. Jean- Jacques Fournie. Cancer Research Center of Toulouse, Toulouse, France.

2 B007 Improved disease-free survival in endometrial and ovarian cancer patients with low folate binding protein expression after treatment with the E39 peptide vaccine in a Phase I/IIa trial. Kaitlin M. Peace 1, Diane F. Hale 1, Timothy J. Vreeland 2, Doreen O. Jackson 1, Julia M. Greene 1, John S. Berry, IV 1, Alfred F. Trappey 1, Garth S. Herbert 1, Guy T. Clifton 1, Mark O. Hardin 3, Kathleen M. Darcy 4, Chad A. Hamilton 4, G. Larry Maxwell 4, George E. Peoples 5. 1 San Antonio Military Medical Center, San Antonio, TX; 2 Womack Army Medical Center, Fayetteville, NC; 3 Madigan Army Medical Center, Tacoma, WA; 4 Gynecologic Cancer Center of Excellence, Annandale, VA; 5 Cancer Vaccine Development Program, San Antonio, TX. B008 Imprime PGG, an intravenously administered beta glucan PAMP activates the innate immune system: A phase I clinical study to evaluate immunopharmacodynamic responses. Nadine C. Ottoson 1, Richard D. Huhn 1, Jamie Lowe 1, Ben Harrison 1, Jose Iglesias 1, Blaine Rathmann 1, Takashi Kangas 1, Lindsay R. Wurst 1, Xiaohong Qiu 1, Anissa Chan 1, Adria Bykowski Jonas 1, Kathryn Fraser 1, Richard M. Walsh 1, Katie Ertelt 1, Steven M. Leonardo 1, Ross Fulton 1, Keith Gorden 1, Mark A. Matson 2, Mark Uhlik 1, Jeremy Graff 1, Nandita Bose 1. 1 Biothera Pharmaceuticals, Inc, Eagan, MN; 2 Prism Clinical Research, Minneapolis, MN. B009 Phase I clinical trial of a PSA, IL-2, GM-CSF containing prostate cancer vaccine in PSA defined biochemical recurrent prostate cancer patients. Jonathan F. Head 1, Gregory A. Daniels 2, Michelle McKinney 2, Weg Ongkeko 3, Kyoko Sakamoto 3, Jessica Wang-Rodriguez 4. 1 Oncbiomune Pharmaceuticals, Baton Rouge, LA; 2 Moores Cancer Center, University of California San Diego, La Jolla, CA; 3 Department of Surgery, University of California San Diego, La Jolla, CA; 4 Department of Pathology, University of California San Diego, La Jolla, CA. B010 Antitumor activity and immune correlates of PEGylated human IL-10 (AM0010) alone or in combination with anti-pd-1. Aung Naing 1, Jeffrey R. Infante 2, Kyriakos P. Papadopoulos 3, Deborah J. Wong 4, Karen A. Autio 5, Gerald S. Falchook 6, Manish Patel 7, Shubham Pant 8, Amita Patnaik 3, Melinda Whiteside 9, Johanna C. Bendell 2, John Mumm 9, Ivan H. Chan 9, Gail L. Brown 9, Peter VanVlasselaer 9, J. R. Hecht 4, David S. Hong 1, Nizar M. Tannir 1, Martin Oft 9. 1 MD Anderson Cancer Center, Houston, TX; 2 Sarah Cannon Research Institute / Tennessee Oncology, PLLC;, Nashville, TN; 3 START Center for Cancer Care, San Antonio, TX; 4 University of California Los Angeles (UCLA), Los Angeles, CA; 5 Memorial Sloan-Kettering Cancer Center, New York, NY; 6 Sarah Cannon Research Institute at HealthONE, Denver, CO; 7 Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; 8 MD Anderson Cancer Center, Houston, CA; 9 ARMO, Palo Alto, CA. This abstract is being presented as a short talk in Session 5 of the scientific program. NEW AGENTS AND THEIR MODE OF ACTION IN ANIMALS AND HUMAN B011 Human IL-2 mutant exhibits a higher antitumor efficacy and lower toxicity than wildtype IL-2 in different preclinical contexts. Tania Carmenate 1, Magela Montalvo 1, Gertrudis Rojas 1, Dasha Fuentes 2, Kalet Leon 1. 1 Center of Molecular Immunology, Habana, Cuba; 2 Centro Nacional para Animales de Laboratorio, Habana, Cuba. B012 Preclinical study of Kiatomab, a novel monoclonal antibody to the cancer stem cell surface marker KIAA1114, for anti-cancer therapy in colorectal carcinoma. Young Min Kim 1, Sae Won Kim 1, Seungwon Lee 2, Hyekang Kim 2, Ji-Hae Kim 1, Han Wook Park 2, Young Chul Sung 1, Seung-Woo Lee 1. 1 POSTECH, Pohang, Korea, Republic of; 2 Pohang University of Science and Technology, Pohang, Korea.

3 B013 Targeting FSTL1 augments therapeutic activities of immune checkpoint inhibitors. Chie Kudo-Saito, Yamato Ogiwara, Marina Hennmi, Kazunori Aoki. National Cancer Center, Tokyo, Japan. This abstract is being presented as a short talk in Session 7 of the scientific program. B014 Improved therapeutic activity of agonistic, human anti-cd40 monoclonal Abs by selective Fc receptorengagement. Rony Dahan, Jeffrey V. Ravetch. The Rockefeller University, New York, NY. B015 Expansion and activation of CD103 + dendritic cell progenitors at the tumor site transform tumor response to PD-L1 and BRAF inhibition. Hélène Salmon 1, Juliana Idoyaga 2, Adeeb Rahman 1, Romain Remark 1, Sacha Gnjatic 1, Nina Bhardwaj 1, Joshua Brody 1, Anna Karolina Palucka 3, Florent Ginhoux 4, Miriam Merad 1. 1 Icahn School of Medicine at Mount Sinai, New York, NY; 2 Stanford University School of Medicine, Stanford, CA; 3 The Jackson Laboratory for Genomic Medicine, Farmington, CT; 4 Singapore Immunology Network, Agency for Science, Technology and Research, Singapore, Singapore. B016 Costimulatory T-cell engagement by PRS-343, a CD137 (4-1BB)/HER2 bispecific, leads to tumor growth inhibition and TIL expansion in humanized mouse model. Marlon J. Hinner 1, Rachida-Siham Bel Aiba 1, Corinna Schlosser 1, Thomas Jaquin 1, Andrea Allersdorfer 1, Sven Berger 1, Alexander Wiedenmann 1, Gabriele Matschiner 1, Julia Schüler 2, Ulrich Moebius 1, Christine Rothe 1, Shane A. Olwill 1. 1 Pieris Pharmaceuticals, Inc., Boston, MA; 2 Oncotest GmbH, Freiburg, Germany. B017 Bacterial minicells decrease tumor development and modulate immunity in a mouse mouse model of colon cancer. Mengxi Tian 1, Mohammad W. Khan 1, Shea Grenier 1, Shingo Tsuji 2, Matthew A. Giacalone 2, Kathleen L. McGuire 1. 1 San Diego State University, San Diego, CA; 2 Vaxiion Therapeutics, San Diego, CA. B018 A novel IDO1 inhibitor combined with targeted immunotherapy durably increases survival in a mouse model of glioblastoma. Erik Ladomersky, Lijie Zhai, Galina Gritsina, Kristen L. Lauing, Matthew Genet, C. David James, Derek A. Wainwright. Northwestern University Feinberg School of Medicine, Chicago, IL. B019 LAG3 is an immunotherapeutic target in murine triple negative breast cancers whose activity is significantly enhanced in combination with phosphatidylserine targeting antibodies. Michael J. Gray, Jian Gong, Jeff Hutchins, Bruce Freimark. Peregrine Pharmaceuticals, Tustin, CA. B020 STING activation in the tumor microenvironment using a synthetic human STING-activating cyclic dinucleotide induces potent antitumor immunity. Sarah M. McWhirter 1, Laura Hix Glickman 1, Tony Desbien 1, Kelsey Sivick Gauthier 1, David Kanne 1, Shailaja Kasibhatla 2, Jie Li 2, AnneMarie Culazzo Pferdekamper 2, George Katibah 1, Ed Lemmens 1, Leticia Corrales 1, Meredith Leong 1, Chudi Ndubaku 1, Justin Leong 1, Leonard Sung 1, Lianxing Zheng 3, Charles Cho 2, Yan Feng 3, Jeffery M. McKenna 3, John A. Tallarico 3, Steven L. Bender 2, Thomas W. Dubensky, Jr Aduro Biotech, Berkeley, CA; 2 Genomics Institute of the Novartis Research Foundation, San Diego, CA; 3 Novartis Institutes for BioMedical Research, Cambridge, MA. B021 Single domain antibodies targeting CTLA-4 demonstrate a critical role for Fc in the antitumor response. Michael Dougan 1, Jessica Ingram 1, Olga Blomberg 1, Mohammad Rashidian 1, Edmund Keliher 2, Ralph Weissleder 2, Steven Almo 3, Hidde Ploegh 1. 1 MIT Whitehead Institute for Biomed. Research, Cambridge, MA; 2 Massachusetts General Hospital, Boston, MA; 3 Albert Einstein College of Medicine, New York, NY.

4 B022 Intratumoral CD40 activation and checkpoint blockade induces systemic anti-melanoma immunity that eradicates disseminated tumors. Manisha Singh, Christina Vianden, Adi Diab, Patrick Hwu, Willem W. Overwijk. University of Texas MD Anderson Cancer Center, Houston, TX. B023 Antibody blockade of Semaphorin 4D enhances infiltration of APC and CD8 T cells and reduces immune suppression to facilitate immune-mediated tumor rejection. Elizabeth E. Evans 1, Holm Bussler 1, Crystal Mallow 1, Christine Reilly 1, Sebold Torno 1, Ekaterina Klimatcheva 1, Maria Scrivens 1, Cathie Foster 1, Alan Howell 1, Leslie Balch 1, Alyssa Knapp 1, John E. Leonard 1, Mark J. Paris 1, Terrence L. Fisher 1, Siwen Hu-Lieskovan 2, Antoni Ribas 2, Ernest S. Smith 1, Maurice Zauderer 1. 1 Vaccinex, Rochester, NY; 2 David Geffen School of Medicine at UCLA, Los Angeles, CA. B024 First-in-class antibody targeting soluble NKG2D ligand smic to enhance checkpoint cancer immunotherapy. Jennifer D. Wu, Jinyu Zhang, Fahmin Basher, Mark Rubinstein. Medical University of South Carolina, Charleston, SC. B025 p53 responsive endogeneous retrovirus as early mediators of immunosurveillance. Kojiro Tashiro, Robyn Leary, Anindya Bagchi. University of Minnesota, Minneapolis, MN. B026 MDSCs and CD8 effector memory T cells correlate with survival in melanoma patients treated with ipilimumab. Yago Pico De Coaña 1, Maria Wolodarski 1, Isabel Poschke 2, Yuya Yoshimoto 3, Giuseppe Masucci 1, Johan Hansson 1, Rolf Kiessling 1. 1 Karolinska Institutet, Stockholm, Sweden; 2 German Cancer Research Center, Heidelberg, Germany; 3 Gunma University Graduate School of Medicine, Gunma, Japan. B027 BGB324, a selective small molecule inhibitor of AXL receptor tyrosine kinase, enhances immune checkpoint inhibitor efficacy. Katarzyna Wnuk-Lipinska 1, Kjersti Davidsen 2, Magnus Blø 1, Linn Hodneland 1, Agnete Engelsen 2, Jing Kang 2, Maria Lie 2, Sebastien Bougnaud 2, Kristina Aguilera 1, Lavina Ahmed 1, Agata Rybicka 1, Elina Milde 1, Paulina Deyna 1, Anna Boniecka 1, Oddbjørn Straume 2, Salem Chouaib 3, Rolf Brekken 4, Gro Gausdal 1, James Lorens 2. 1 BerGenBio AS, Bergen, Norway; 2 University of Bergen, Bergen, Norway; 3 Institut Gustave Roussy, Paris, France; 4 UT Southwestern Medical Center, Dallas, TX. B028 Blockade of the CD47 Do not eat signal by TTI-621 (SIRPαFc) leads to enhanced antitumor CD8 + T cell responses in vitro. Natasja Nielsen Viller, Tran Truong, Emma Linderoth, Lisa D. Johnson, Stephane Viau, Gloria H. Y. Lin, Mark Wong, Xinli Pang, Penka S. Petrova, Robert A. Uger. Trillium Therapeutics Inc., Mississauga, ON, Canada. B029 OMX: An oxygen carrier biotherapeutic that ameliorates the hypoxic tumor microenvironment and promotes anticancer T cell activity. Kevin G. Leong, Natacha Le Moan, Yuqiong Pan, Philberta Leung, Catherine Bedard, Jon Winger, Stephen P.L. Cary, Ana Krtolica. Omniox Inc, San Carlos, CA. B030 Development and validation of a phenotypic screening platform for the identification of novel immunooncology targets. Virginie Rabolli, Murielle Martini, Ariane Scoumanne, Marie-Claire Letellier, Stefano Crosignani, Christophe Quéva, Michel Detheux, Jakub M. Swiercz, Sandra Cauwenberghs. iteos Therapeutics, Gosselies, Belgium. B031 FAK/PYK2 inhibition enhances antitumor efficacy of anti-pd-1 and anti-4-1bb antibodies. Jonathan A. Pachter, David T. Weaver. Verastem, Inc., Needham, MA.

5 B032 The PI3K-γ inhibitor, IPI-549, increases antitumor immunity by targeting tumor-associated myeloid cells and remodeling the immune-suppressive tumor microenvironment. Matthew Rausch 1, Jeremy Tchaicha 1, Thomas Tibbitts 1, Olivier De Henau 2, Sujata Sharma 1, Melissa Pink 1, Joseph Gladstone 1, Jennifer Proctor 1, Mark Douglas 1, Howard Stern 1, Taha Merghoub 2, Jedd Wolchok 2, Karen McGovern 1, Jeff Kutok 1, David Winkler 1. 1 Infinity Pharmaceuticals, Inc, Cambridge, MA; 2 Memorial Sloan Kettering Cancer Center, New York, NY. B033 A novel IL-2 and IL-15 antagonist shifting the immune balance towards tolerance: Potential therapeutic applications. Meghnem Dihia, Sebastien Morisseau, Kilian Trillet, Marie Frutoso, Isabelle Barbieux, Agnes Quemener, Yannick Jacques, Erwan Mortier. INSERM, Nantes, France. B034 Smac mimetics synergistically improve the efficacy of cancer immunotherapies including immune checkpoint blockade in preclinical models. Eric LaCasse, Shawn Beug, Cristin Healey, Caroline Beauregard, Tarun Sanda, Tommy Alain, Robert Korneluk. Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada. B035 CXCL8/CXCR1 signaling promotes angiogenesis and hematopoietic stem and progenitor cell function. Bradley W. Blaser 1, Jessica L. Moore 1, Elliott Hagedorn 1, Brian Li 1, Vera Binder 2, Owen Tamplin 3, Leonard I. Zon 1. 1 Boston Children's Hospital, Boston, MA; 2 Dr. von Hauner Children's Hospital, Ludwig-Maximillian's University, Munich, Germany; 3 University of Illinois College of Medicine, Chicago, IL. NON-CHECKPOINT IMMUNOTHERAPIES B036 Neo-antigen landscape dynamics during human melanoma-t cell interactions. Els M.E. Verdegaal 1, Noel de Miranda 1, Marten Visser 1, Tom Harryvan 1, Marit van Buuren 2, Rikke Andersen 3, Sine Hadrup 3, Caroline van der Minne 1, Remko Schotte 4, Hergen Spits 4, John Haanen 2, Ellen Kapiteijn 1, Ton Schumacher 2, Sjoerd H. Van Der Burg 1. 1 Leiden University Medical Center, Leiden, Netherlands; 2 Netherlands Cancer Institute, Amsterdam, Netherlands; 3 University Hospital Herlev, Copenhagen, Denmark; 4 AIMM Therapeutics, Amsterdam, Netherlands. B037 Macrophage repolarization therapy in metastatic colorectal cancer: CCR5 inhibition. Niels Halama 1, Inka Zoernig 1, Anna Berthel 1, Christoph Kahlert 2, Fee Klupp 3, Meggy Suarez-Carmona 1, Juergen Krauss 1, Karsten Brand 4, Felix Lasitschka 5, Tina Lerchl 1, Claudia Luckner-Minden 1, Alexis Ulrich 6, Juergen Weitz 2, Martin Schneider 7, Markus W. Buechler 7, Laurence Zitvogel 8, Thomas Herrmann 9, Axel Benner 10, Christina Kunz 10, Stephan Luecke 10, Christoph Springfeld 1, Christine Falk 11, Dirk Jaeger 1. 1 National Center for Tumor Diseases, Heidelberg, Germany; 2 University Hospital Dresden, Dresden, Germany; 3 University Hospital Heidelberg, Heidelberg, Germany; 4 Institute for Pathology, University Hospital, Heidelberg, Germany; 5 Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany; 6 University Hospital, Department of Surgery, Heidelberg, Germany; 7 University Hospital Heidelberg, Department of Surgery, Heidelberg, Germany; 8 Institute Gustave Roussy, Paris, France; 9 Klinikum Heide, Heide, Germany; 10 German Cancer Research Center, Heidelberg, Germany; 11 Medical School Hannover, Hannover, Germany. This abstract is being presented as a short talk in Session 6 of the scientific program. B038 Class IIa HDAC inhibition promotes an antitumor macrophage phenotype that induces breast tumor regression and inhibits metastasis. Jennifer L. Guerriero, Alaba Sotayo, Holly Ponichtera, Alexandra Pourzia, Sara Schad, Ruben Carrasco, Suzan Lazo, Roderick Bronson, Anthony Letai. Dana-Farber Cancer Institute, Boston, MA.

6 B039 Small-molecule inhibitors of CD73 promote activation of human CD8+ T cells and have profound effects on tumor growth and immune parameters in experimental tumors. Juan C. Jaen, Jay P. Powers, Ada Chen, Manmohan R. Leleti, Jarek Kalisiak, Ulrike Schindler, Joanne Bl Tan, Steve Young, Shin-Heng Chiou, Laurent Debien. Arcus Biosciences, Inc., Hayward, CA. This abstract is being presented as a short talk in Session 6 of the scientific program. B040 Imiquimod initiates tumor specific overload of the ER stress response in Tasmanian devil facial cancer cells. Amanda L. Patchett 1, Terry L. Pinfold 1, Cesar Tovar 1, Bruce Lyons 2, Gregory M. Woods 1. 1 Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia; 2 School of Medicine, University of Tasmania, Hobart, Australia. B041 Ibrutinib treatment counteracts the immunosuppressive activity of malignant B cells. Meixiao Long, Kyle A. Beckwith, Priscilla Do, Amber Gordon, Amy Lehman, Kami Maddocks, Carolyn Cheney, Jeffrey Jones, Leslie Andritsos, Farrukh Awan, Jennifer Woyach, Johnson J. Amy, Natarajan Muthusamy, John Byrd. The Ohio State University, Columbus, OH. B042 Potent and selective small molecule USP7 inhibitors for cancer immunotherapy. Suresh Kumar 1, Jian Wu 1, Liqing Wang 2, Jack Wang 1, Ivan Sokirniy 1, Hui Wang 1, Glen Fegley 1, Joseph Weinstock 1, Michael Mattern 1, Wayne W. Hancock 2. 1 Progenra Inc, Malvern, PA; 2 Children's Hospital of Philadelphia, Philadelphia, PA. B043 Systems pharmacology modeling of anti-cd20/cd3 T-cell dependent bispecific antibody and its application to clinical trial design. Iraj Hosseini, Kapil Gadkar, Eric Stefanich, Chi-Chung Li, Laura Sun, Yu-Waye Chu, Saroja Ramanujan. Genentech Inc., San Francisco, CA. B044 Patient-specific immunotherapy through TCR gene transfer. Lorenzo F. Fanchi 1, Laura Bies 2, Ji-Ying Song 1, Carsten Linnemann 2, Ton Schumacher 1. 1 Netherlands Cancer Institute, Amsterdam, Netherlands; 2 Kite Pharma, Amsterdam, Netherlands. B045 Arginase inhibitor CB-1158 elicits immune-mediated antitumor responses as a single agent and in combination with other immunotherapies. Susanne M. Steggerda, Mark Bennett, Jason Chen, Ethan Emberley, Matthew Gross, Tony Huang, Weiqun Li, Andy MacKinnon, Amani Makkouk, Gisele Marguier, Silinda Neou, Alison Pan, Tracy Wang, Melissa Works, Jing Zhang, Winter Zhang, Francesco Parlati. Calithera Biosciences, South San Francisco, CA. B046 Therapeutic mechanisms of anti-4-1bb antibodies in cancer: Agonism versus regulatory T cell depletion. Marcus Remer, Anne Rogel, Sarah Buchan, Peter W.M. Johnson, Aymen Al-Shamkhani. University of Southampton, Southampton, United Kingdom. B047 Combining natural killer T cell immunotherapy with chemotherapy induced immunogenic cell death to target post-surgical breast cancer metastasis. Simon Gebremeskel 1, Kaitlyn Tanner 2, Lynnea Lobert 2, Brent Johnston 2. 1 Beatrice Hunter Cancer Research Institute, Halifax, NS, Canada; 2 Dalhousie University, Halifax, NS, Canada.

7 B048 A novel PI3K delta inhibitor suppresses tumor progression by immune modulation. ZuSheng Xu 1, Yangtong Lou 1, Jie Tan 2, Chong Wang 2, Xiaomei Ge 2, Ying Gu 2, He Zhou 2. 1 Shanghai Yingli Pharmaceuticals Co. Ltd, Shanghai, China; 2 Shanghai ChemPartner Co. Ltd, Shanghai, China. B049 Immunotherapy of EBV associated gastric cancer using EBV specific T cells. Jae Seung Moon, Jung Ho Kim, Sang Kyou Lee. Yonsei University, Seoul, Korea. B050 Functional characterization of virus specific stem cell like memory T cells, their maturation in vitro, and potential contribution to secondary T cell responses. Tzu-yun Kuo 1, Aisha N. Hasan 2, Richard J. O'Reilly 2. 1 Weill Cornell Medical College, New York, NY; 2 Memorial Sloan Kettering Cancer Center, New York, NY. B051 Super cross-presentation of tumor antigens by synthetic design of an anti-phosphatidylserine bridge protein. Daniel Corey 1, Aaron Ring 2, Melissa McCracken 1, Masanori Miyanishi 1, Sydney Gordon 1, Irving Weissman 1. 1 Stanford University, Institute for Stem Cell Biology and Regenerative, Stanford, CA; 2 Yale University, Department of Immunobiology, New Haven, CT. B052 Peroxisome proliferator-activated receptor delta agonist GW enhances the efficacy of adoptive cell therapy. Samuel Saibil, Michael St. Paul, Pamela Ohahsi. Princess Margaret Cancer Centre, Toronto, ON, Canada. B053 Characterizing the effects of the DNA methylation inhibitor 5-AZA-CdR during CD8 T cell expansion. Helen Loo Yau. University of Toronto, Toronto, ON, Canada. B054 Evaluation of NY-BR-1 as a suitable antigen for CAR based immunotherapy. Patrick Schmidt 1, Claudia Luckner Minden 1, Claudia Ziegelmeier 1, Isabella Gosch 1, Niels Halama 1, Frank Momburg 2, Rosa Eurich 2, Sarah Schott 3, Frederik Marmé 3, Andreas Schneeweiß 3, Claus Peter Heußel 4, Dirk Jäger 1, Inka Zörnig 1. 1 Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany; 2 Clinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3 Department of Obstetrics and Gynecology, National Center for Tumor Diseases, Heidelberg, Germany; 4 Department of Diagnostic and Interventional Radiology with Nuclear Medicine, Thoraxklinik and Heidelberg University Hospital, Heidelberg, Germany, Heidelberg, Germany. B055 Augmentation of OX40-dependent NK mediated antitumor activity is dependent on antibody crosslinking. Sean H. Lim 1, Anna H. Turaj 1, Jane Willoughby 1, Claude H.T. Chan 1, Christine A. Penfold 1, Peter W.M. Johnson 1, Martin J. Glennie 1, Mark S. Cragg 1, Ronald Levy 2. 1 University of Southampton, Southampton, United Kingdom; 2 Stanford University, Stanford, CA. B056 Harnessing tissue resident memory T cells to combat solid tumors. Pamela C. Rosato, Luke S. Manlove, Christine E. Nelson, Christopher A. Pennell, Vaiva Vezys, David Masopust. University of Minnesota, Minneapolis, MN. B057 The CD122-biased immunostimulatory cytokine NKTR-214 combined with checkpoint blockade leads to mobilization of antitumor immunity and synergistic activity. John L. Langowski, Murali Addepalli, Laurie VanderVeen, Rhoneil Pena, Ravikumar Nutakki, Yolanda Kirksey, Ute Hoch, Jonathan Zalevsky, Stephen K. Doberstein, Deborah H. Charych. Nektar Therapeutics, San Francisco, CA.

8 B058 Development of AVID200, a novel and highly potent TGF-beta neutralizing immunotherapy. Maureen D. O'Connor-McCourt 1, Anne E.G. Lenferink 2, John Zwaagstra 2, Traian Sulea 2, Jason Baardsnes 2, Catherine Collins 2, Christiane Cantin 2, Lucie Couture 2, Limei Tao 2, Yves Durocher 2, Renu Singh 2, James Koropatnick 3. 1 Formation Biologics, Montreal, QC, Canada; 2 National Research Council of Canada, Montreal, QC, Canada; 3 Lawson Health Research Institute, London, ON, Canada. B059 Local intratumoral treatment with low-dose CD40 and TLR4 agonists overcomes resistance to PD-1 blockade to regress tumors systemically. Danny N. Khalil, Luis Felipe Campesato, Yanyun Li, Taha Merghoub, Jedd D. Wolchok. Memorial Sloan Kettering Cancer Center, New York, NY. B060 Small molecule inhibitors of the anti-inflammatory TAM receptor MerTK. Sacha J. Holland, Alexander M. Owyang, Sylvia Braselmann, Chrystelle Lamagna, Sothy Yi, Chi Young, Roy Frances, Arthur Bagos, Meagan Chan, Ernest Tai, Stacey Siu, Gary Park, David Lau, Matt Duan, Rao Kolluri, Jiaxin Yu, Ihab Darwish, Somasekhar Bhamidipati, Donald G. Payan, Esteban Masuda. Rigel Pharmaceuticals, Inc., S. San Francisco, CA. B061 CD81: A new target for therapy of B cell lymphoma. Felipe Vences-Catalán, Chiung-Chi Kuo, Ranjani Rajapaksa, Ronald Levy, Shoshana Levy. Stanford University, Stanford, CA. B062 Immune activation by LMP1 CD40 pathway and LMP1-IPS-1 STING pathway activators. Richard S. Kornbluth 1, Sachin Gupta 2, James M. Termini 2, Elizabeth Guirado 2, Geoffrey W. Stone 2. 1 Receptome, LLC, La Jolla, CA; 2 Miller School of Medicine, University of Miami, Miami, FL. B063 Oncolytic adenoviruses armed with tumor necrosis factor alpha and interleukin-2 enable successful adoptive T cell therapy of solid tumors. Mikko Siurala 1, Riikka Havunen 2, João Santos 1, Siri Tähtinen 2, Dipongkor Saha 2, Markus Vähä-Koskela 2, Michael Behr 3, Dirk M. Nettelbeck 3, Anja Ehrhardt 4, Suvi Parviainen 1, Akseli Hemminki 1. 1 TILT Biotherapeutics Ltd, Helsinki, Finland; 2 Cancer Gene Therapy Group, Faculty of Medicine, University of Helsinki, Helsinki, Finland; 3 German Cancer Research Center (DKFZ), Heidelberg, Germany; 4 Witten/Herdecke University, Witten, Germany. B064 Induction of protective antitumor immunity through attenuation of endoplasmic reticulum aminopeptidase 1 function. Gessa Sugiyarto, Ian Bailey, Tim Elliott, Edward James. University of Southampton, Southampton, United Kingdom. B065 Use of simultaneous detection of externalized CD107a and CD137 for evaluation of specificity and effector functions of polyclonal T-cells produced for adoptive cellular immunotherapy of prostate cancer. Pavla Taborska, Dmitry Stakheev, Katerina Vavrova, Petra Vrabcova, Jirina Bartunkova, Daniel Smrz. 2nd Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic. B066 The hexavalent CD40 agonist APG1233 is a superior inducer of immune cell activation compared to trimeric formats or agonistic anti-cd40 antibodies. Christian Merz, Jaromir Sykora, Meinolf Thiemann, David M. Richards, Thamara Beyer, Stefanie Kühn, Harald Fricke, Christian Gieffers, Oliver Hill. Apogenix AG, Heidelberg, Germany.

9 B067 Preclinical data of novel enantiomeric oligonucleotides for cancer immunotherapy: The TLR9 agonist EnanDIM. Kerstin Kapp 1, Barbara Volz 1, Detlef Oswald 1, Burghardt Wittig 2, Manuel Schmidt 1. 1 MOLOGEN AG, Berlin, Germany; 2 Foundation Institute Molecular Biology and Bioinformatics, Freie Universitaet Berlin, Berlin, Germany. B068 Hydrocortisone, prednisolone, methylprednisolone, and dexamethasone inhibit CetuGEX -mediated ADCC in vitro. Christoph Goletz, Johanna Rühmann, Beate Habel, Antje Danielczyk, Steffen Goletz. Glycotope, Berlin, Germany. B069 The best is not enough when it is alone: Current clinical doses of humanized anti-her2 antibodies should be applied in combination to delay development of trastuzumab resistance by additively enhancing ADCC. Gábor Tóth 1, Árpád Szöőr 1, László Simon 1, Yosef Yarden 2, János Szöllősi 1, György Vereb 1. 1 University of Debrecen, Debrecen, Hungary; 2 Weizmann Institute of Science, Rehovot, Israel. TRIALS IN PROGRESS B070 IPI A Phase 1/1b first in human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with an anti-pd-1 antibody in subjects with advanced solid tumors. Anthony Tolcher 1, David Hong 2, Ryan Sullivan 3, James Mier 4, Geoffrey Shapiro 5, Joseph Pearlberg 6, Les Brail 6, Jahnavi Kharidia 6, Lixin Han 6, Claudio Dansky Ullmann 6, Howard M. Stern 6, Jedd D. Wolchok 7. 1 South Texas Accelerated Research Therapeutics (START), San Antonio, TX; 2 MD Anderson Cancer Center, Houston, TX; 3 Massachusetts General Hospital, Boston, MA; 4 Beth Israel Deaconess Medical Center, Boston, MA; 5 Dana-Farber Cancer Institute, Boston, MA; 6 Infinity Pharmaceuticals, Inc., Cambridge, MA; 7 Memorial Sloan Kettering Cancer Center, New York, NY. B072 Phase Ib trial of the RNActive cancer vaccine BI (CV9202) and local radiotherapy in patients with stage IV non-small cell lung cancer (NSCLC) with disease control after first-line chemotherapy or during therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: Updated clinical results and immune responses. M. M. Hipp 1, M. Sebastian 2, C. Weiss 3, M. Früh 4, M. Pless 5, R. Cathomas 6, W. Hilbe 7, G. Pall 7, T. Wehler 8, J. Alt 8, H. Bischoff 9, M. Geißler 10, F. Griesinger 11, J. Kollmeier 12, A. Papachristofilou 13, F. Doener 1, M. Fotin-Mleczek 1, H. S. Hong 1, K. J. Kallen 1, U. Klinkhardt 14, S. D. Koch 1, E. Niehus 14, B. Scheel 1, A. Schröder 14, T. Seibel 14, U. Gnad- Vogt 14, A. Zippelius CureVac AG, Tübingen, Germany; 2 Department of Hematology/Oncology, J.W. Goethe University Hospital Frankfurt, Frankfurt, Germany; 3 Centre of Radiology, University Hospital Frankfurt, Frankfurt, Germany; 4 Department of Oncology and Hematology, Cantonal Hospital of St Gallen, St Gallen, Switzerland; 5 Department of Medical Oncology, Cantonal Hospital of Winterthur, Winterthur, Switzerland; 6 Department of Internal Medicine, Cantonal Hospital Graubünden, Chur, Switzerland; 7 Department of Internal Medicine V (Haematology and Oncology), University Hospital Innsbruck, Innsbruck, Austria; 8 Third Department of Internal Medicine, Johannes Gutenberg-University Hospital Mainz, Mainz, Germany; 9 Department of Internal Medicine/Oncology, Thoraxklinik- Heidelberg GmbH, Heidelberg, Germany; 10 Department of Oncology and Gastroenterlogy, Klinikum Esslingen GmbH, Esslingen, Germany; 11 Department of Hematology and Oncology, Pius Hospital, Oldenburg, Germany; 12 Department of Pneumology, Heckeshorn Lung Clinic, Berlin, Germany; 13 Department of Radio-Oncology, University Hospital Basel, Basel, Switzerland; 14 CureVac AG, Frankfurt, Germany; 15 Department of Oncology, University Hospital Basel, Basel, Germany.

10 EMERGING TECHNOLOGIES Poster Session B B073 Protein nanoparticles for controllable T cell activation. Marc J. Lajoie, Gabriel Butterfield, Elizabeth Gray, Kate DaPron, Daniel Stetson, David Baker, Neil King. University of Washington, Seattle, WA. B074 Automatic identification of cell niches and immune interactions important for clinical outcomes using multiparameter imaging and deep neural networks. Salil S. Bhate, Nikolay Samusik, Yury Goltsev, Garry P. Nolan. Stanford University, Stanford, CA. This abstract is being presented as a short talk in Session 8 of the scientific program. B075 Conversion of extracellular signals to programmable genome manipulation via CRISPRouter. P C Dave P. Dingal, Nathan Kipniss, Yuchen Gao, Lei S. Qi. Stanford University, Stanford, CA. B076 PIN-2: A novel immunopriming peptide with immunomodulatory activity linking the innate and adaptive immune systems. Joshua B. Goldberg, Sophie Hanscom, Colin B. Bier. PIN Pharma, Inc., New York, NY. B077 Non-invasive imaging of the PD-1/PD-L1 pathway in syngeneic murine tumor models. Sandra Heskamp, Janneke D.M. Molkenboer-Kuenen, Erik H. Aarntzen, Otto C. Boerman. Radboud university medical center, Nijmegen, Netherlands. B078 GoTCR: Inducible MyD88/CD40 (imc) enhances proliferation and survival of tumor-specific TCR-modified T cells and improves antitumor efficacy in myeloma. Tsvetelina Pentcheva-Hoang 1, David Torres 1, Tania Rodriguez 1, Ana Korngold 1, An Lu 1, Jeannette Crisostomo 1, Annemarie Moseley 1, Lorenz Jahn 2, Mirjam H.M. Heemskerk 2, Kevin Slawin 1, David Spencer 1, Aaron Foster 1. 1 Bellicum Pharmaceuticals, Houston, TX; 2 Leiden University Medical Center, Leiden, Netherlands. B079 The efficacy of CD133 BiTEs and CAR-T cells in preclinical model of recurrent glioblastoma. Parvez Vora 1, Chirayu Chokshi 1, Maleeha Qazi 1, Chitra Venugopal 1, Sujeivan Mahendram 1, Mohini Singh 1, Jarrett Adams 2, David Bakhshinyan 1, Max London 2, Minomi Subapanditha 1, Nicole McFarlane 1, James Pan 2, Jonathan Bramson 1, Jason Moffat 2, Sachdev Sidhu 2, Sheila Singh 1. 1 McMaster University, Hamilton, ON, Canada; 2 University of Toronto, Toronto, ON, Canada. B080 Noninvasive imaging of antitumor responses as a possible predictive tool. Mohammad Rashidian, Hidde Ploegh. Whitehead Institute/MIT, Cambridge, MA. B081 Spatially-resolved, multiplexed (up to 800 plex) digital characterization of protein and mrna abundance in FFPE tissue sections: Application to immuno-oncology. Dwayne Dunaway, Jaemyeong Jung, Chris Merritt, Isaac Sprague, Philippa Webster, Sarah Warren, Joseph Beechem. NanoString Technologies, Seattle, WA. B082 Migratory T cells demonstrate superior persistence and enhanced tumor control. Gabrielle Romain 1, Harjeet Singh 2, Ivan Liadi 1, Jay R Adolacion 1, Laurence J.N. Cooper 3, Navin Varadarajan 1. 1 University of Houston, Houston, TX; 2 University of Texas MD Anderson Cancer Center, Houston, TX; 3 Ziopharm Oncology, Boston, MA.

11 B083 Novel mrna manufacturing techniques using modification of nucleosides and purification improves the efficacy of mrna chimeric antigen receptor T cells. Jessica Foster, Namrata Choudhari, David Barrett, Adam Resnick. The Children's Hospital of Philadelphia, Philadelphia, PA. B084 Transparent tumor tomography (T3): Spatial analysis for PD-L1 checkpoint blockade immunotherapy. Steve Seung-Young Lee. The University of Chicago, Chicago, IL. B085 Combining transcriptomic profiling and genome engineering to dissect regulation of tumor immunology. Le Cong, Meromit Singer, Chao Wang, John Kwon, Ana Anderson, Orit Rozenblatt-Rosen, Vijay Kuchroo, Aviv Regev. Broad Institute, Cambridge, MA. B086 CRISPR-Cas9 engineering and screening in primary human T cells. Cristina Ghirelli, Thibault Laurent, Kim Hoenderdos, Chris Lowe, Nicola McCarthy, Jonathan Moore. Horizon Discovery, Cambridge, United Kingdom. B087 Revealing antibody repertoires and RAG tracking by linear amplification mediated-high-throughput genome-wide translocation sequencing. Jiazhi Hu, Sherry G. Lin, Zhaoqing Ba, Zhou Du, Yu Zhang, Frederick W. Alt. Boston Children's Hospital, Boston, MA. B088 Generation of immuno-modulatory receptor binding bispecific antibodies to modulate tumor immunity. Rinse Klooster, Cecile Geuijen, Mark Throsby. Merus NV, Utrecht, Netherlands. B089 High-throughput profiling of HLA allele-specific peptides by MS for improved epitope prediction. Michael S. Rooney 1, Jennifer G. Abelin 1, Derin B. Keskin 2, Siranush Sarkizova 3, Christina Hartigan 4, Wandi Zhang 5, John Sidney 6, Jonathan Stevens 7, William J. Lane 8, Guang L. Zhang 9, Karl R. Clauser 4, Nir Hacohen 10, Steven A. Carr 4, Catherine J. Wu 2. 1 Neon Therapeutics, Cambridge, MA; 2 Dana-Farber Cancer Institute, Boston, MA; 3 Harvard Medical School, Boston, MA; 4 Broad Institute of MIT and Harvard, Cambridge, MA; 5 Dana-Farber Cancer Institute,, Boston, MA; 6 La Jolla Institute for Allergy and Immunology, La Jolla, CA; 7 Brigham and Women's Hospital, Boston, MA; 8 Brigham and Women s Hospital, Boston, MA; 9 Boston University, Boston, MA; 10 Center for Cancer Immunology at Massachusetts General Hospital, Cambridge, MA. B090 Evaluation of a novel impedance-based assay for label free and dynamic assessment of CAR-T constructs efficacy against B-cell leukemia and lymphoma. Chelsea Xue 1, Fabio Cerignoli 2, Vladimir Senyukov 3, Piotr Pierog 1, Thomas Miller 3, Amy Shaw 1, Biao Xi 2, Lincoln Muir 2, Yama Abassi 2, Sadik Kassim 1. 1 Novartis, Cambridge, MA; 2 ACEA Biosciences, San Diego, CA; 3 Novartis, Morris Plain, NJ. B091 A LAG-3/PD-L1 bispecific antibody inhibits tumor growth in two syngeneic colon carcinoma models. Jacqueline Doody, Matthew Kraman, Katy Everett, Carlo Zimarino, Katarzyna Kmiecik, Mustapha Faroudi, Paul Thompson, Mateusz Wydro, Francisca Wollerton, Carlos Gaspar, Mihriban Tuna. F-star Biotechnology Ltd., Cambridge, United Kingdom. B092 Therapeutic targeting of tumorigenic EphA2+/EphA3+ brain tumor initiating cells with bi-specific antibody in glioblastoma. Parvez Vora 1, Maleeha Qazi 1, Chirayu Chokshi 1, Chitra Venugopal 1, Max London 2, Amy Hu 2, Nicole McFarlane 1, Minomi Subapanditha 1, Mohini Singh 1, Sujeivan Mahendram 1, Jarrett Adams 2, Jason Moffat 2, Sachdev Sidhu 2, Sheila Singh 1. 1 McMaster University, Hamilton, ON, Canada; 2 University of Toronto, Toronto, ON, Canada.

12 B093 In vitro testing solid cancers immunotherapy protocols through impedance technology allows dynamic and label-free evaluation of immune response and reagent efficacy. Fabio Cerignoli, Biao Xi, Garret Guenther, Trent Rector, Lincoln Muir, Leyna Zhao, Yama Abassi. ACEA Biosciences Inc., San Diego, CA. B094 Targeted expression and molecular profiling assay for tumor microenvironment. Alex Chenchik, Andrey Komarov, Michael Makhanov, Sunitha Sastry, Costa Frangou. Cellecta, Inc., Mountain View, CA. B095 Multiplexed detection of RNA and proteins on the ncounter platform with low sample input protocol. Sarah Warren, Gary Geiss, Brian Burditt, Qian Mei, Alan Huang, Maribeth Eagen, Eduardo Ignacio, Dwayne Dunaway, Lucas Dennis, Joseph Beechem. NanoString Technologies, Seattle, WA. B096 Optogenetics-based dissection of chemotactic signaling in neutrophils. Brian R. Graziano 1, Delquin Gong 1, Karen E. Anderson 2, Orion D. Weiner 1. 1 UCSF, San Francisco, CA; 2 The Babraham Institute, Babraham, Cambridge, United Kingdom. B097 Analyze and recover functionally defined single immune cell clones through Opto-Electro-Positioning technology. Xiaohua Wang, Yelena Bronevetsky, Guido Stadler, Kristin Beaumont, Xiaoyan Robert Bao, Saki Shimizu, Duane Smith, Kevin Chapman. Berkeleylights Inc, Emeryville, CA. B098 A panel of well characterized syngeneic models for in vivo screening analysis: MuScreen TM. Ying Jin, Lan Zhang, Juan Zhang, Eric Murphy, Zhongliang Li, Meng Qiao, Qian Shi. Crown Biosciences, Taicang, China. B099 The UniCAR system: Inducible CAR T cells for precise reactivity and high efficacy against hematopoietic malignancies. Simon Loff 1, Malte v. Bonin 2, Josephine Dietrich 3, Jan-Erik Meyer 3, Anja Feldmann 4, Claudia Arndt 4, Johannes Spehr 3, Cordula Gründer 1, Gerhard Ehninger 2, Michael P. Bachmann 4, Armin Ehninger 1, Marc Cartellieri 3. 1 GEMoaB monoclonals GmbH, Dresden, Germany; 2 Medical Clinic and Policlinic I, University Hospital Carl Gustav Carus, Dresden, Germany; 3 Cellex Patient Treatment GmbH, Dresden, Germany; 4 Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany. B100 An intrinsic safeguard for chimeric antigen receptor adoptive T-cell immunotherapies. Julien Valton. Cellectis, New York, NY. B101 Mechanism of T cell activation by phase separation. Xiaolei Su 1, Jonathon Ditlev 2, Enfu Hui 1, Michael Rosen 2, Ronald Vale 1. 1 UCSF, San Francisco, CA; 2 UT Southwestern Medical Center, Dallas, TX. B102 A microengineered human lymph node-on-a-chip to study cancer immunotherapy. Girija Goyal 1, Donald Ingber 2. 1 Harvard University, Cambridge, MA; 2 Wyss Institute, Harvard University, Cambridge, MA. MECHANISTIC MERGING OF TREATMENT MODALITIES B103 Intralesional administration of CTLA-4 blocking monoclonal antibodies as a means to optimize bladder cancer therapy. Luuk van Hooren 1, Linda Sandin 1, Igor Moskalev 2, Peter Ellmark 3, Anna Dimberg 1, Peter Black 2, Thomas H. Tötterman 1, Sara M. Mangsbo 1. 1 Uppsala University, Uppsala, Sweden; 2 University of British Columbia, Vancouver, BC, Canada; 3 Alligator Bioscience AB, Lund, Sweden.

13 B104 Impact of PD-1 blockade on epigenetic and transcriptional reprogramming of exhausted T cells. Kristen E. Pauken 1, Morgan A. Sammons 1, Pamela M. Odorizzi 1, Sasi K. Manne 1, Jernej Godec 2, Omar Khan 1, Debattama Sen 2, Makoto Kurachi 1, R. Anthony Barnitz 2, Bertram Bengsch 1, Alexander C. Huang 1, Jason M. Schenkel 3, Golnaz Vahedi 1, W. Nicholas Haining 2, Shelley L. Berger 1, E. John Wherry 1. 1 University of Pennsylvania, Philadelphia, PA; 2 Harvard Medical School, Boston, MA; 3 University of Minnesota, Minneapolis, MN. B105 HSP90 inhibitor, ganetespib, enhances responses to cancer immunotherapy through increased expression of interferon response genes. Rina M. Mbofung 1, Jodi A. McKenzie 1, Shruti Malu 2, Chengwen Liu 1, Weiyi Peng 1, Isere Kuiatse 1, Leila Williams 1, Seram Devi 1, Zhe Wang 1, Trang Tieu 1, Tim Heffernan 1, Richard E. Davis 1, Rodabe Amaria 1, Patrick Hwu 1. 1 MD Anderson Cancer Center, Houston, TX; 2 Dana Farber Cancer Institute, Boston, MA. B106 Substantial enrichment of HIV- resistant CD4 T cells by combining the targeted integration of a resistance-cassette at the CCR5 locus with chemoselection. Biswajit Paul 1, Guillermo Romano Ibarra 2, David J. Rawlings 2, Hans-Peter Kiem 1. 1 Fred Hutchinson Cancer Center, Seattle, WA; 2 Seattle Childrens Research Institute, Seattle, WA. B107 Immunotransplant: Merging checkpoint blockade and T-cell transfer into lymphodepleted recipients. Netonia Marshall, Thomas Marron, Judith Agudo, Brian Brown, Joshua Brody. Ichan School of Medicine, Mt. Sinai Hospital, New York, NY. B108 The HDAC inhibitor HBI-8000 enhances immunotherapy with either PD-1 or PD-L1 blockade in the MC38 model of colon cancer. Reid P. Bissonnette, Alain Rolland, Bob Goodeneow, Mireille Gillings. HUYA Bioscience International, San Diego, CA. B109 Epigenetic reprogramming of T-cells from metastatic melanoma patients enhances central memory and decreases Th2/Treg phenotypes. Andressa L. Sodre 1, David M. Woods 1, Amod Sarnaik 2, Brian C. Betts 2, Jeffrey S. Weber 1. 1 NYU Langone Medical Center, New York, NY; 2 Moffitt Cancer Center, Tampa, FL. B110 Topoisomerase I inhibitors enhance efficacy of immunotherapy through a p53 regulatory pathway. Jodi A. McKenzie 1, Rina M. Mbofung 1, Shruti Malu 2, Rodabe N. Amaria 1, Emily L. Ashkin 1, Seram N. Devi 1, Weiyi Peng 1, Leila J. Williams 1, Richard E. Davis 1, Jason Roszik 1, Trang N. Tieu 1, Timothy Heffernan 1, Patrick Hwu 1. 1 University of Texas MD Anderson Cancer Center, Houston, TX; 2 Dana-Farber Cancer Institute, Boston, MA. B111 HDAC inhibitors modulate immune checkpoint blockade in breast cancer. Manuela Terranova Barberio 1, Scott Thomas 1, Niwa H. Ali 1, Jeenah Park 1, Michael D. Rosenblum 1, Alfredo Budillon 2, Pamela N. Munster 1. 1 University of California San Francisco, San Francisco, CA; Istituto Tumori Napoli G. Pascale, Naples, Italy. B112 Targeting immunotherapy to the tumor microenvironment using anti-pdl1 VHH. Michael Dougan 1, Jessica Ingram 1, Hidde Ploegh 1, Stephanie K. Dougan 2. 1 Whitehead Institute for Biomedical Research, Cambridge, MA; 2 Dana-Farber Cancer Institute, Boston, MA.

14 B113 Translational studies demonstrate that treatment with anti-pd-1 in unresponsive tumors can be improved by enhancing T cell activation in the tumor microenvironment with vaccine based immune therapy. Genevieve Weir 1, Olga Hrytsenko 1, Richard van der Jagt 2, Matthew Cheung 3, Rena Buckstein 3, Tara Quinton 1, Lisa MacDonald 1, Rita Nigam 1, Marc Mansour 1, Neil L. Berinstein 3, Marianne Stanford 1. 1 Immunovaccine Inc., Halifax, NS, Canada; 2 Ottawa Hospital Research Institute, Ottawa, ON, Canada; 3 Sunnybrook, Toronto, ON, Canada. B114 Innate immunity modulators to enhance oncolytic VSV-GP for the treatment of ovarian cancer. Janine Kimpel 1, Carles R. Urbiola 1, Catherine Dold 1, Christian Marth 1, Alexander Muik 2, Dorothee Holm-von Laer 1, Guido Wollmann 1. 1 Medical University Innsbruck, Innsbruck, Austria; 2 Paul Ehrlich Institute, Langen, Germany. B115 Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Jing Liu 1, Stephen Blake 1, Michelle Yong 1, Heidi Harjunpaa 1, Shin Foong Ngiow 1, Kazuyoshi Takeda 2, Arabella Young 1, Stacey Allen 1, Mark J. Smyth 1, Michele WL Teng 1. 1 QIMR Berghofer Medical Research Institute, Brisbane, Australia; 2 Juntendo University, Tokyo, Japan. B116 Immunovirotherapy in combination with immune checkpoint inhibitors for treating glioblastoma. Dipongkor Saha, Robert Martuza, Samuel Rabkin. Massachusetts General Hospital and Harvard Medical School, Boston, MA. B117 Evaluating the in vitro effects of tumor-treating fields on T-cell responses. Gil Diamant, Ilan Volovitz, Zvi Ram. Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. B118 Using a high throughput T-cell cytotoxicity assay to develop combination strategies for immunotherapy. Leila Williams 1, Shruti Malu 2, Jodi McKenzie 1, Rina Mbofung 1, Jason Roszik 1, Patrick Hwu 1. 1 MD Anderson Cancer Center, Houston, TX; 2 Dana-Farber Cancer Institute, Boston, MA. B119 Characterization of a phosphatidylserine, TAM receptor (Tyro3, Axl, Mertk), PDL1 axis in breast cancer. Canan Kasikara 1, Sushil Kumar 1, Ke Geng 1, Viral Davre 1, Cyril Empig 2, Bruce Freimark 2, Michael Gray 2, Kyle Schlunegger 2, Jeff Hutchins 2, Sergei V. Kotenko 1, Raymond B. Birge 1. 1 Rutgers, New Jersey Medical School, Newark, NJ; 2 Peregrine Pharmaceuticals, Tustin, CA. B120 Synergistic potentiation of the anti-metastatic effect of anti EGFR mabs by its combination with immunotherapies targeting the ganglioside NGcGM3. Addys Gonzalez, Rances Blanco, Adriana Carr, Kalet Leon. Center of Molecular Immunology, Habana, Cuba. OTHER TOPICS B121 Oncogenic MYC contributes to tumor super-enhancers via erna amplification. Yang Eric Guo, Michael Seyffert, Brian Abraham, Xiong Ji, Richard Young. Whitehead Institute MIT, Cambridge, MA. B122 Molecular mechanism of V(D)J recombination from synaptic RAG1-RAG2 complex structures. Heng Ru 1, Melissa G. Chambers 2, Tian-Min Fu 1, Alexander B. Tong 1, Maofu Liao 2, Hao Wu 1. 1 Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School; Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA; 2 Department of Cell Biology, Harvard Medical School, Boston, MA.

15 B123 Engineering phagocytic signaling. Adam Williamson, Ron Vale. UCSF, San Francisco, CA. This abstract is being presented as a short talk in Session 8 of the scientific program. B124 Roles for Tnfsf11 expression by group 3 innate lymphoid cells. Jennifer K. Bando 1, Christina Song 2, Susan Gilfillan 1, Marco Colonna 1. 1 Washington University School of Medicine, St. Louis, MO; 2 AbbVie, Redwood City, CA. B125 The relationship between members of the canonical NF-κB pathway, components of the microenvironment and survival in patients with colorectal cancer. Jean A. Quinn, Lindsay Bennett, Antonia Roseweir, James H. Park, Paul G. Horgan, Donald C. McMillan, Joanne Edwards. University of Glasgow, Glasgow, United Kingdom. B126 Correlation of tumor growth inhibition by check point inhibitors with PD-L1 expression in preclinical patient derived xenograft (PDX) models. Maria Stecklum, Annika Wulf-Goldenberg, Bernadette Brzezicha, Iduna Fichtner, Jens Hoffmann. EPO GmbH, Berlin, Germany. B127 Free DNA and tolerance. Gilberto Filaci, Francesca Ferrera, Samuele Tardito, Tiziana Altosole, Cinzia Bernardi, Alessia Parodi, Daniela Fenoglio. University of Genoa, Italy, Genova, Italy. B128 Clinical translation of oncolytic measles virus for T cell activation. Christine E. Engeland, Rūta Veinalde, Christof von Kalle, Dirk Jaeger, Guy Ungerechts. National Center for Tumor Diseases, Heidelberg, Germany. B129 Multiple immune checkpoint receptors are co-expressed on tumor antigen-specific T cells and contribute to tumor immune evasion. Robert J. Durso, Jerry Pei, Michelle Russell, Pratha Budhani, Elena Burova, Chandrika Taduriyasas, Ella Ioffe, Markus Mohrs, Gavin Thurston, Jie Dai. Regeneron Pharmaceuticals, Inc., Tarrytown, NY. B130 Dysregulated Toll-like receptor responses as an oncogenic driver. Olivia Majer, Bo Liu, Angus Yiu-fai Lee, Greg Barton. University of California, Berkeley, Berkeley, CA. B131 Quantitative modeling of Syk regulation in B cell chronic lymphocytic leukemia. Maria P. Frushicheva. Massachusetts Institute of Technology, Cambridge, MA. B132 Importance and mechanism of poly(a) tail length-mediated translational control in different immune cells. Kehui Xiang, David Bartel. Whitehead Institute for Biomedical Research, Cambridge, MA. B133 Regulation of antiviral immune responses by RNase L. Jonathan Clingan 1, Sterling Eckard 1, Daphne Cooper 2, Hilario Ramos 1, Jaime Guillen 3, Bruno Canard 3, Michael Gale, Jr. 1, Jay Hesselberth 2, David Barton 2, Daniel Stetson 1. 1 University of Washington, Seattle, WA; 2 University of Colorado School of Medicine, Aurora, CO; 3 Aix- Marseille Universite, Marseille, France. B134 Cryo-EM structure of the activated NAIP2-NLRC4 inflammasome reveals nucleated polymerization. Liman Zhang 1, Shuobing Chen 2, Jianbin Ruan 1, Liron David 1, Youdong Mao 3, Hao Wu 1. 1 Boston Children's hospital, Boston, MA; 2 Peking University, Beijing, China; 3 Dana-Farber Cancer Institute, Boston, MA.